Projects per year
Fingerprint
Dive into the research topics where Sharad A Ghamande is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 4 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects
-
-
Georgia Regents University Women's Reproductive Health Research Career Development Plan
Diamond, M. P., Diamond, M. P. & Ghamande, S. A.
7/18/15 → 6/30/20
Project: Research project
Research Output
-
A 73-gene proliferative transcriptomic signature predicts uterine serous carcinoma patient survival and response to primary therapy
Tran, L. K. H., Tran, P. M. H., Mysona, D. P., Purohit, S. B., Myers, E., Lee, W. S., Dun, B., Xu, D., Liu, H., Hopkins, D., Nechtman, J., Scelsi, C. L., Mittal, P. K., Kleven, D., Wallbillich, J. J., Rungruang, B., Ghamande, S. & She, J. X., May 2020, In : Gynecologic Oncology. 157, 2, p. 340-347 8 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer
Oza, A. M., Matulonis, U. A., Secord, A. A., Nemunaitis, J., Roman, L. D., Blagden, S. P., Banerjee, S., McGuire, W. P., Ghamande, S., Birrer, M. J., Fleming, G. F., Markham, M. J., Hirte, H. W., Provencher, D. M., Basu, B., Kristeleit, R., Armstrong, D. K., Schwartz, B., Braly, P., Hall, G. D. & 8 others, , Mar 1 2020, In : Clinical Cancer Research. 26, 5, p. 1009-1016 8 p.Research output: Contribution to journal › Article › peer-review
7 Scopus citations -
Clinical calculator predictive of chemotherapy benefit in stage 1A uterine papillary serous cancers
Mysona, D. P., Tran, L. K. H., Tran, P. M. H., Gehrig, P. A., Van Le, L., Ghamande, S., Rungruang, B. J., Java, J., Mann, A. K., Liao, J., Kapp, D. S., Santos, B. D., She, J. X. & Chan, J. K., Jan 2020, In : Gynecologic Oncology. 156, 1, p. 77-84 8 p.Research output: Contribution to journal › Article › peer-review
2 Scopus citations -
EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer
Arend, R. C., Davis, A. M., Chimiczewski, P., O'Malley, D. M., Provencher, D., Vergote, I., Ghamande, S. & Birrer, M. J., Feb 2020, In : Gynecologic Oncology. 156, 2, p. 301-307 7 p.Research output: Contribution to journal › Article › peer-review
2 Scopus citations -
Long term survival outcomes of stage I mucinous ovarian cancer - A clinical calculator predictive of chemotherapy benefit
Richardson, M. T., Mysona, D. P., Klein, D. A., Mann, A., Liao, C. I., Diver, E. J., Darcy, K. M., Tian, C., She, J. X., Ghamande, S., Van Le, L., Kapp, D. S. & Chan, J. K., Oct 2020, In : Gynecologic Oncology. 159, 1, p. 118-128 11 p.Research output: Contribution to journal › Article › peer-review